Table 2 PICOs included on systematic reviews
Population | Intervention | Comparison | Outcomes | Systematic Reviews included | Individual studies included in the systematic review | Conclusion | ||
|---|---|---|---|---|---|---|---|---|
Controlled trials | Uncontrolled trials | Observational studies | ||||||
Patients with localized GIST | Laparoscopic resection | Open resection | Surgery outcomes: blood loss, time to flatus, operative time, time to oral intake, length of hospital stay, complication rate. Oncology outcomes: overall survival, disease-specific survival, local and metastatic recurrence. | Chen 2014, Liang 2013, Othani 2013, Pelletier 2015, Zheng 2014 | Catena 2008, Dai 2011, Goh 2010, Ishikawa 2006, Karakousis 2011, Kasetsermwiriya 2014, Kim 2012, Lee 2011, Lee 2013, Lin 2014, Matthews 2002, Melstrom 2012, Mochizuki 2006, Nishimura 2007, Pitsinis 2007, Pucci 2012, Shimizu 2002, Silberhumer 2009, Shu 2013, Takahashi 2014, De Vogelaere 2013, Wan 2012, Wang 2010, Wu 2010, Xu 2009, Zhao 2011, Zhou 2009, Zong 2011 | Beneficial Probably beneficial | ||
Patients with localized KIT (CD117)-positive GIST after complete surgical resection High risk of relapse after surgery Intermediate risk of relapse after surgery Low risk of relapse after surgery | Imatinib adjuvant | Surgery alone | overall survival, recurrence-free survival, recurrence rates, adverse effects | Essat 2011 | ACOSOG Z99001 (DeMatteo 2009) | ACOSOG Z9000 (DeMatteo 2005), Zhan2006. | Bumming 2003, Kang 2009, Li 2009, Nilsson 2007 | Beneficial |
Imatinib adjuvant | Surgery alone | overall survival, recurrence Seddon2008.free survival, adverse events | Essat 2011, NICE 2014 | ACOSOG Z99001 (DeMatteo 2009, Corless 2010), EORTC 62024 (Casali 2013) | ACOSOG Z9000 (DeMatteo 2005), Nisihda 2009, Yalcin 2012, Zhan 2006 | Bumming 2003, Jiang 2011, Kanda 2013, Kang 2013, Li 2009, Li 2011, Nilsson 2007 | Beneficial Probably beneficial | |
Imatinib adjuvant for ≥3 years | Imatinib adjuvant <3 years | Overall Survival, local recurrence | NICE 2014 | SSGXVIII/AIO (Joensuu 2012, Heintz 2011), | Conley 2012, | Probably beneficial | ||
Imatinib adjuvant | Surgery alone | Recurrence- free survival | Essat 2011 | ACOSOG Z99001b (DeMatteo 2009) | Beneficial | |||
Imatinib adjuvant | Surgery alone | Recurrence- free survival | Essat 2011 | ACOSOG Z99001 (DeMatteo 2009) | No effect | |||
Patients with unresectable and/or metastatic GIST | Imatinib | Current standard treatments | Overall survival, response rate, quality of life, adverse events | Wilson 2005 | Benjamin 2003a (interinm results of Blanke Rankin 2008), Demetri 2002a, Judson 2003, Ryu 2003, Van Oosterom2001, Verweij 2004 | Jankilevich 2003 | Probably beneficial | |
Preoperative imatinib + surgery | Surgery alone | Overall survival, disease-free survival | Cirocchi 2010 | No studies | Inconclusive | |||
Imatinib high dose Imatinib 800 mg /day Imatinib 600 mg/day | Imatinib standard dose Imatinib 400 mg /day Imatinib 400 mg /day | Overall survival, progression free survival, response rate, dose reduction, adverse events Overall survival, progression free survival, adverse events Overall survival, response rate, adverse events | Liu 2013, Yang 2012, Zong 2011 Liu 2013 Liu 2013 | Blanke Demetri 2008,Blanke Rankin 2008, Dagher 2002, Demetri 2002, Nishida 2008, Verweij 2004 Blanke Rankin 2008, .Verweij 2004 Dagher 2002, Demetri 2002, Nishida2008 | Harmful Harmful Harmful | |||
Patients with unresectable and/or metastatic GIST after failure of imatinib due to resistance or intolerance. | Sunitinib + BSC | Imatinib at escalated doses | Overall survival, progression free survival, response rate and adverse effects. | Abdel- Rahman2015, Hislop 2011/2012 | EORTC-ISG-AGITG (Zalcberg 2005, Debiec Rychter 2006), Blanke Rankin 2008a, B2222a (Blanke Demetri 2008, Demetri 2006) | Hsu 2014, Vincenzi 2014, Park2009, Seddon2008. | Probably beneficial No effect | |
Sunitinib + BSC | BSC/ placebo | Overall survival, progression free survival, response rate, quality of life, adverse events | NICE 2009, Abdel-Rahman 2015, Wu 2014 | Demetri 2006 (interim of Demetri 2012), Demetri 2012 | Reichardt 2008 | Beneficial Probably beneficial | ||
Masinitib | Sunitinib | Overall survival | Abdel –Rahman 2015 | Adenis 2014 | Probably beneficial | |||
Patients with unresectable and/or metastatic GIST after failure of imatinib and sunitinib due to resistence or intolerance | Resumption of previous imatinib 400 mg | Placebo | Overall survival, progression free survival, response rate, adverse effects. | Abdel Rahman 2015 | Kang 2013 | Probably beneficial | ||
Regorafenib + BSC | BSC/ placebo | Overall survival, progression free survival, and adverse effects. | Abdel-Rahman 2015, Crona 2013, Wu 2014) | Demetri 2013 | George 2012 | Probably beneficial | ||
Nilotinib | Placebo | Overall survival, progression free survival, response rate, adverse effects. | Abdel-Rahman 2015, Wu 2014 | Reichardt 2012 | No effect Inconclusive | |||